Inivata
Clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 228 % | 150 % | 118 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (45486 %) | (14806 %) | (6768 %) | (2884 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (43766 %) | (13011 %) | (6820 %) | (2932 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 69 % | 21 % | 17 % | 39 % |
Source: Company filings or news article
Related Content
Inivata is a pioneering company in the field of liquid biopsy, a technology that extracts key genomic information from a simple blood test to revolutionize cancer care. The company primarily serves patients with advanced Non-Small Cell Lung Cancer (NSCLC) and high-grade ovarian carcinomas (HGOC). Operating in the healthcare and biotechnology markets, Inivata collaborates with medical institutions and pharmaceutical companies to provide cutting-edge diagnostic solutions. Its business model revolves around the development and commercialization of liquid biopsy assays, which are used for detecting residual disease and recurrence in cancer patients. Revenue is generated through the sale of these diagnostic tests and through strategic partnerships and collaborations, such as the one with Maverick Therapeutics. Inivata's innovative approach and commitment to improving patient outcomes make it a leader in its field.
Keywords: liquid biopsy, cancer care, genomic insights, NSCLC, HGOC, diagnostic solutions, biotechnology, healthcare, residual disease, Maverick Therapeutics.